This may be here:
TABLE - Genome Therapeutics Corp. Q3 loss
Reuters Story - July 06, 1998 15:05
%&64 %DRU %US %RES GENE V%REUTER P%RTR
WALTHAM, Mass., July 6 (Reuters) -
(in thousands, except share and per share amounts)
Thirteen weeks ended Thirty-nine weeks ended
May 30, May 31, May 30, May 31,
1998 1997 1998 1997
Revenues:
Collaborative research,
licenses, subscription
fees & royalties $4,658 $2,987 $12,516 $9,816
Government research 352 919 815 4,230
Total revenues 5,010 3,906 13,331 14,046
Costs and expenses:
Research and development
8,090 5,978 22,561 14,483
Cost of government
research 352 919 815 4,230
Selling, general and
administrative 1,178 997 3,313 2,587
Total costs and
expenses 9,620 7,894 26,689 21,300
Loss from operations
(4,610) (3,988) (13,358) (7,254)
Interest income 552 741 1,881 2,271
Interest expense (307) (159) (846) (431)
Net loss (4,365) (3,406) (12,323) (5,414)
Basic/diluted net loss
per common share (0.24) (0.19) ( 0.68) (0.31)
Basic/diluted
weighted average
number of common
shares outstanding
18,274,085 17,666,731 18,181,749 17,569,640
((--New York Newsdesk (212) 859-1700)) |
